Table 11.
Treatment groups | AI | CRI |
---|---|---|
I | 2.1 ± 0.1 | 4.0 ± 0.2a+ |
II | 1.6 ± 0.2 | 3.2 ± 0.2e− |
III | 2.0 ± 0.2 | 3.5 ± 0.2d− |
IV | 1.9 ± 0.3 | 3.9 ± 0.3 |
V | 2.1 ± 0.1 | 3.8 ± 0.1d− |
VI | 2.0 ± 0.1 | 3.8 ± 0.2d− |
VII | 1.8 ± 0.1 | 3.8 ± 0.2d− |
VIII | 1.1 ± 0.0 | 3.5 ± 0.1 |
a+A significant increase at p < 0.05 when compared to the untreated negative (normal) control values. d−,e−Significant decreases at p < 0.05 and p < 0.01, respectively, when compared to the untreated positive (doxorubicin treated only) control values, respectively.